Pembrolizumab benefit holds long-term for some melanoma patients
The anti–PD-1 immunotherapy pembrolizumab increases long-term survival in some patients with advanced melanoma, according to updated results of KEYNOTE-001.
Among the 655 patients studied in the phase 1b trial, the 3-year overall survival rate for advanced melanoma patients treated with <a...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Dermatology | Immunotherapy | Melanoma | Skin | Skin Cancer